Articles & Video
Showing 21 of 93 articles & video
Worldwide Clinical Trials expands cancer research site network in Europe
US CRO Worldwide Clinical Trials has signed deals with research organization in Europe to expand its cancer drug study network.
CROs that foster an inclusive culture make clinical trials more diverse
Better planning can help CROs and sponsors make clinical trials inclusive according to new research which suggests organizations need to really commit to make drug studies more diverse.
Icon cites AI as key to efforts to boost access to trials
Icon says artificial intelligence helped it increase patient access to clinical trials over the past 12 months.
PE firms to buy Syneos Health in $7.1bn deal
Private equity investors have bought US trial contractor Syneos Health in a deal that values the CRO at $7.1 billion.
Henko invests in Popsicube and Missiontec in next stage of pan-European CRO project
Private equity firm Henko Partners has invested in French trial services firms Popsicube and Missiontec and unveiled plans to build a “pan-European” CRO.
US FDA shows support for DCTs with new draft guideline
The US FDA has underlined its support for decentralized trials with new draft guidelines designed to encourage industry to study drugs in a more patient-centric way.
Sanofi teams with Flatiron to reimagine data transfer in cancer trials
Sanofi has called on AI developer Flatiron Health to help it find better ways of designing and managing data transfer in cancer drug trials.
Ampersand backs Belgian CRO P95 BV with eye on expansion
Private equity firm Ampersand Capital Partners will invest in vaccine and infectious disease contractor P95 BV in a deal designed to expand CROs offering.
IBD drug developers, CROs and regulators must team to solve trial challenges says study
Difficulties finding patients for clinical trials is holding back the development of treatments for inflammatory bowel disease (IBD) say researchers who say increased collaboration is key to reversing the trend.
Trial regs and CRO management are challenges for vaccine developers, study says
Running vaccine trials in developing countries is a significant challenge due to complex regulations and CRO management difficulties according to new analysis.
Non-traditional sites a path to more diverse clinical trials, say researchers
Efforts to make clinical trials more diverse need to intensify according to researcher, who suggest the EMPACTA study in patients with COVID-19 proves the value of focused recruitment.
DCTs worth the investment according to Tufts study
Decentralized methods make financial sense for most Phase II and III clinical trials according to analysis, which suggests spending money on site-free studies generate a seven-fold return on investment.
Trial activity, R&D spending soar in 2022, but diversity issues remain
A decline in COVID-19 related trial work was more than offset by a surge in drug studies, spending and successful completions last year according to market analysis.
Livingbridge backs UK biostats CRO Veramed
Private equity group Livingbridge has invested in UK biostatistics and programming CRO Veramed.
Thread buys Modus Outcomes in latest effort to grow global DCT business
Thread has bought clinical outcomes consultancy Modus Outcomes in a bid to further expand its decentralized trials business.
Site staff diversity vital for trial participant diversity according to Tufts
Clinical trial participant diversity is closely linked with the ethnic diversity of site staff according to research by Tufts Center for the Study of Drug Development (CSDD) in the US.
Europe approves Goldman and EQT’s Parexel takeover
The European Commission has approved Goldman Sachs and EQT’s acquisition of Parexel from Pamplona capital management.
AstraZeneca sets up Indian clinical data insights division
AstraZeneca has set up an insights division in Bengaluru, India to manage some “data-related aspects” of clinical trials.
Blackstone buys Australian Phase I trial firm Nucleus Network
The Blackstone Group has acquired Nucleus Network, an Australian Phase I clinical trials business from Crescent Capital Partners.
Advarra launches site selection platform
Advarra has launched a platform to help trial sponsors identify sites that fit their clinical programs.